VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 187 filers reported holding VAXCYTE INC in Q1 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $234,442,338 | +5.9% | 4,598,712 | +3.8% | 0.05% | +11.9% |
| Q2 2023 | $221,294,679 | +82.3% | 4,431,211 | +36.8% | 0.04% | +75.0% |
| Q1 2023 | $121,407,989 | -28.2% | 3,239,274 | -8.2% | 0.02% | -29.4% |
| Q4 2022 | $169,173,067 | +303.0% | 3,528,114 | +101.7% | 0.03% | +277.8% |
| Q3 2022 | $41,974,000 | +1392.7% | 1,748,921 | +1253.4% | 0.01% | +800.0% |
| Q2 2022 | $2,812,000 | -89.8% | 129,221 | -88.7% | 0.00% | -80.0% |
| Q1 2022 | $27,648,000 | +0.8% | 1,144,815 | -0.7% | 0.01% | +25.0% |
| Q4 2021 | $27,431,000 | +4.1% | 1,153,025 | +11.1% | 0.00% | 0.0% |
| Q3 2021 | $26,340,000 | +33.3% | 1,038,221 | +18.2% | 0.00% | +33.3% |
| Q2 2021 | $19,766,000 | +0.2% | 878,125 | -12.0% | 0.00% | 0.0% |
| Q1 2021 | $19,720,000 | -26.6% | 998,410 | -1.2% | 0.00% | -40.0% |
| Q4 2020 | $26,859,000 | -50.5% | 1,010,850 | -7.9% | 0.01% | -54.5% |
| Q3 2020 | $54,212,000 | +42.9% | 1,097,856 | -8.5% | 0.01% | +37.5% |
| Q2 2020 | $37,932,000 | – | 1,200,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |